Cécile Jovelet

1.2k total citations
31 papers, 416 citations indexed

About

Cécile Jovelet is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Cécile Jovelet has authored 31 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Cancer Research and 7 papers in Oncology. Recurrent topics in Cécile Jovelet's work include Lung Cancer Treatments and Mutations (25 papers), Cancer Genomics and Diagnostics (22 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Cécile Jovelet is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Cancer Genomics and Diagnostics (22 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). Cécile Jovelet collaborates with scholars based in France, Spain and United Kingdom. Cécile Jovelet's co-authors include Ludovic Lacroix, Jean‐Charles Soria, Benjamin Besse, Jordi Remón, Karen Howarth, David Planchard, Sophie Gil, Etienne Rouleau, Fabrice André and Claudio Nicotra and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Cécile Jovelet

29 papers receiving 411 citations

Peers

Cécile Jovelet

PRM

ONCOL

PFM

Laure Sorber Belgium

Maria Farooq United States

Christine Vietz United States

Feng Lou China

Lisanne F. van Dessel Netherlands

Olivier Bouché France

Nicole Caixeiro Australia

Uwe Thiel Germany

Fanny Garlan France

Laure Sorber Belgium

Cécile Jovelet

420 ×1.7

211 ×1.0

PRM

172 ×0.9

ONCOL

291 ×2.1

82 ×1.5

PFM

Citations per year, relative to Cécile Jovelet Cécile Jovelet (= 1×) peers Laure Sorber

Countries citing papers authored by Cécile Jovelet

Since Specialization

Citations

This map shows the geographic impact of Cécile Jovelet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cécile Jovelet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cécile Jovelet more than expected).

Fields of papers citing papers by Cécile Jovelet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cécile Jovelet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cécile Jovelet. The network helps show where Cécile Jovelet may publish in the future.

Co-authorship network of co-authors of Cécile Jovelet

This figure shows the co-authorship network connecting the top 25 collaborators of Cécile Jovelet. A scholar is included among the top collaborators of Cécile Jovelet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cécile Jovelet. Cécile Jovelet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Velden, Bas H. M. van der, Sandra M. van den Bosch, Alexander Sartori, et al.. (2024). Predicting response to neoadjuvant chemotherapy with liquid biopsies and multiparametric MRI in patients with breast cancer. npj Breast Cancer. 10(1). 10–10. 10 indexed citations

Riudavets, Mariona, Damien Vasseur, Édouard Auclin, et al.. (2022). Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer. 23(6). e377–e383. 1 indexed citations

Jovelet, Cécile, et al.. (2022). Abstract 75: Highly multiplexed EGFR mutation detection from liquid biopsy samples using the 6-color Crystal Digital PCR™. Cancer Research. 82(12_Supplement). 75–75.

Vasseur, Damien, Mihaela Aldea, Charles Naltet, et al.. (2021). 1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy. Annals of Oncology. 32. S991–S991. 1 indexed citations

Géraud, Arthur, Laura Mezquita, Édouard Auclin, et al.. (2020). Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers. 12(12). 3758–3758. 3 indexed citations

Remón, Jordi, Aurélie Swalduz, David Planchard, et al.. (2020). Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE. 15(6). e0234302–e0234302. 14 indexed citations

Géraud, Arthur, Laura Mezquita, Édouard Auclin, et al.. (2019). MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance. Journal of Thoracic Oncology. 14(10). S337–S338. 1 indexed citations

Enrico, Diego, Ludovic Lacroix, Étienne Rouleau, et al.. (2019). Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study. Annals of Oncology. 30. v627–v627. 5 indexed citations

Mezquita, Laura, David Planchard, Mihaela Aldea, et al.. (2019). Clinical utility of ctDNA genomic alterations (GA) based on ESMO scale for clinical actionability of molecular targets (ESCAT) in advanced NSCLC. Annals of Oncology. 30. ix122–ix123. 5 indexed citations

10.

Remón, Jordi, Caroline Caramella, Cécile Jovelet, et al.. (2017). Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA. Annals of Oncology. 28(4). 784–790. 133 indexed citations

11.

Jovelet, Cécile, Jordan Madic, Jordi Remón, et al.. (2017). Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer. PLoS ONE. 12(8). e0183319–e0183319. 26 indexed citations

12.

Koeppel, Florence, Steven G. Blanchard, Cécile Jovelet, et al.. (2017). Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS ONE. 12(11). e0188174–e0188174. 81 indexed citations

13.

Denis, M., Audrey Vallée, Sandrine Charpentier, et al.. (2017). Nationwide external quality assessment (EQA) of EGFR testing in circulating tumor DNA: The French experience. Annals of Oncology. 28. v32–v32. 1 indexed citations

14.

Remón, Jordi, Benjamin Besse, Ludovic Lacroix, et al.. (2017). Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting.. Journal of Clinical Oncology. 35(15_suppl). 11532–11532. 1 indexed citations

15.

Mezquita, Laura, Cécile Jovelet, Maud Ngo‐Camus, et al.. (2017). MA 11.01 Liquid Biopsies for Monitoring BRAF Mutation (V600E) in Advanced BRAF (V600E) Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(11). S1843–S1843. 1 indexed citations

16.

Fu, Yu, Cécile Jovelet, Thomas Filleron, et al.. (2016). Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. Cancer Research. 76(20). 5954–5961. 11 indexed citations

17.

Jovelet, Cécile, Sophie Broutin, Sophie Gil, Olivier Mir, & Angélo Paci. (2016). Inhibiteurs de tyrosine kinase et grossesse : quels risques pour le fœtus ?. Bulletin du Cancer. 103(5). 478–483. 2 indexed citations

18.

Jovelet, Cécile, Atmane Seck, Olivier Mir, et al.. (2015). Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Annals of Oncology. 26(7). 1500–1504. 21 indexed citations

19.

Jovelet, Cécile, Alain Deroussent, Sophie Broutin, et al.. (2013). Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. European Journal of Drug Metabolism and Pharmacokinetics. 38(3). 149–157. 10 indexed citations

20.

Jovelet, Cécile, Jean Bénard, F Forestier, et al.. (2012). Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. European Journal of Pharmaceutical Sciences. 46(5). 484–491. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact